AriBio

Overview

AriBio Co., Ltd. is a South Korean biotechnology company headquartered in Seoul, South Korea, dedicated to developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2015, AriBio focuses on innovative approaches targeting protein aggregation and neuroprotection[@aribio].

The company has advanced its lead candidate AR1001 through clinical development and is building a pipeline of next-generation therapies for Alzheimer's disease.

Pipeline Overview

| Program | Target/Mechanism | Indication | Stage | Status |
|---------|-----------------|------------|-------|--------|
| AR1001 | PDE5 inhibitor | Alzheimer's disease | Phase 2/3 | Active |
| AR1002 | Tau aggregation inhibitor | Alzheimer's disease | Preclinical | Research |
| AR1003 | Anti-amyloid antibody | Alzheimer's disease | Discovery | Research |

Lead Program: AR1001

Mechanism of Action

AR1001 is a phosphodiesterase 5 (PDE5) inhibitor being developed for Alzheimer's disease. PDE5 inhibition is believed to provide neuroprotective effects through multiple pathways[@pde2024]:

• Increased cGMP signaling: Enhanced cyclic GMP levels promote neuronal survival
• Improved cerebral blood flow: Vasodilation in cerebral vasculature
• Anti-inflammatory effects: Reduced neuroinflammation
• Synaptic protection: Enhanced synaptic plasticity and function
• Tau phosphorylation modulation: Effects on tau pathology

Clinical Development

Overview

AriBio Co., Ltd. is a South Korean biotechnology company headquartered in Seoul, South Korea, dedicated to developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2015, AriBio focuses on innovative approaches targeting protein aggregation and neuroprotection[@aribio].

The company has advanced its lead candidate AR1001 through clinical development and is building a pipeline of next-generation therapies for Alzheimer's disease.

Pipeline Overview

| Program | Target/Mechanism | Indication | Stage | Status |
|---------|-----------------|------------|-------|--------|
| AR1001 | PDE5 inhibitor | Alzheimer's disease | Phase 2/3 | Active |
| AR1002 | Tau aggregation inhibitor | Alzheimer's disease | Preclinical | Research |
| AR1003 | Anti-amyloid antibody | Alzheimer's disease | Discovery | Research |

Lead Program: AR1001

Mechanism of Action

AR1001 is a phosphodiesterase 5 (PDE5) inhibitor being developed for Alzheimer's disease. PDE5 inhibition is believed to provide neuroprotective effects through multiple pathways[@pde2024]:

• Increased cGMP signaling: Enhanced cyclic GMP levels promote neuronal survival
• Improved cerebral blood flow: Vasodilation in cerebral vasculature
• Anti-inflammatory effects: Reduced neuroinflammation
• Synaptic protection: Enhanced synaptic plasticity and function
• Tau phosphorylation modulation: Effects on tau pathology

Clinical Development

Phase 2/3 Trial (2024-2025):

• Randomized, double-blind, placebo-controlled study
• Primary endpoints: Cognitive function (ADAS-Cog13), functional capacity (ADCS-ADL)
• Enrollment: Patients with mild-to-moderate Alzheimer's disease
• Results expected: 2025-2026

• Completed single and multiple ascending dose studies
• Demonstrated favorable safety and tolerability
• Good brain penetration achieved

Clinical Rationale

The PDE5 target in Alzheimer's disease is supported by multiple lines of evidence:

• PDE5 expression is elevated in AD brains
• cGMP signaling is reduced in AD
• PDE5 inhibition improves memory in animal models
• Crosses the [blood-brain barrier](/entities/blood-brain-barrier) effectively

AR1002: Tau Aggregation Inhibitor

Program Overview

AR1002 targets [tau protein](/proteins/tau) aggregation, a key pathological feature of Alzheimer's disease. This program is in preclinical development[@tau2023].

Mechanism:

• Inhibits tau protein aggregation
• Promotes tau clearance
• May reduce neurofibrillary tangle formation

• Lead optimization completed
• IND-enabling studies planned

Science and Research

Alzheimer's Disease Focus

AriBio's approach to Alzheimer's disease addresses multiple pathological hallmarks:

Research Collaborations

AriBio maintains collaborations with:

• Academic institutions in South Korea
• Contract research organizations for clinical trials
• International partners for global development

Corporate Information

Headquarters: Seoul, South Korea

Founded: 2015

Leadership:

• Dr. Han-Oh Park, CEO
• Scientific Advisory Board with Alzheimer's experts

• Series A: Private financing
• Series B: Growth financing
• Public listing: KOSPI (planned)

Competitive Landscape

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Eli Lilly | [Donanemab](/entities/donanemab) | Anti-[Aβ](/proteins/amyloid-beta) mAb | Approved |
| Biogen/Eisai | [Lecanemab](/entities/lecanemab) | Anti-Aβ mAb | Approved |
| Cassava Sciences | Simufilam | Filamin A mod | Phase 3 |
| Roche | Gantenerumab | Anti-Aβ mAb | Phase 3 |
| AriBio | AR1001 | PDE5 inhibitor | Phase 2/3 |

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• PDE5 Inhibitors in CNS
• [Biogen](/companies/biogen)
• [Eli Lilly](/companies/eli-lilly)
• [Cassava Sciences](/companies/cassava-sciences)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving AriBio discovered through SciDEX knowledge graph analysis: